THE NEXT GENERATION OF PHARMA

Biomind Labs is developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules.

RECENT HIGHLIGHTS:

• Biomind Labs Unveils Groundbreaking Advancements in Neurologucal Disorder Treatments
• Revolutionary Clinical Trial: Biomind Labs Targets Depression and Anxiety in Alzheimer's with Proprietary 5-MeO-DMT Formulation 
• Biomind Labs Achieves Breakthrough Extraction Method for Triptax™, Enhancing Purity and Yield of DMT

WHY BIOMIND?

Commitment to provide patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use, by developing: A unique portfolio of potent psychedelic molecules aimed at providing patients with access to affordable and modern day neuropsychiatric treatments.

The most diversified pipeline of clinical trials targeting multiple diseases to seek fast-track approvals and breakthrough therapy designations for novel pharmaceuticals

Complex products, on-demand products, and customized products, controlling the time and place of drug release for the specific needs of each patient

A personalized medicine and a sustainable production to provide a democratic access to our novel pharmaceuticals regardless the income level of patients

Biomind Labs Announced Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

A Robust IP Strategy